Anhui Anke Bio-engineering announced that its wholly-owned subsidiary has received approval for its Acetic Acid Treprostinil API. This approval grants market access in China, enriching the company's peptide API pipeline and boosting API sales. The company anticipates this will expand its peptide business and enhance competitiveness.
Summary generated by AI · Always verify with source document
Announcement on the Approval for Listing of Acetic Acid Treprostinil API by Wholly-Owned Subsidiary
Securities Code: 300009 Securities Abbreviation: Anke Bio Announcement No.: 2026-034
Anhui Anke Bio-engineering (Group) Co., Ltd.
The Board of Directors and all members of the company guarantee the authenticity, accuracy, and completeness of the public disclosure information, and there are no false records, misleading statements or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.